CVS Caremark picks Wegovy over Zepbound on its main drug lists
One of the largest pharmacy benefit managers made Wegovy its preferred obesity drug, so many members on Zepbound faced a switch or an exception request.
Who feels it
-
Patients
Rethink
If your plan uses this list and you take Zepbound, you may need to switch or ask for an exception.
-
Prescribers
Rethink
Expect switch requests and exception paperwork for patients doing well on tirzepatide.
-
Sellers
Rethink
A clear win for one maker on volume; the other pushes patients to its cash channel.
-
Pharmacies
Adjust
Prepare for a wave of changed prescriptions around the start date.
-
Payers
Adjust
Lower net cost in return for limiting choice; some employers may opt out.
The decision
CVS Caremark said that from 1 July 2025, Wegovy would be the preferred GLP-1 for weight loss on its standard drug lists. Zepbound moved off those lists for that use.
Why a benefit manager does this
Pharmacy benefit managers trade placement on their lists for lower prices from makers. Picking one product over a close rival usually means a better net price on the winner.
What patients face
- People already on Zepbound could be asked to switch to Wegovy.
- Doctors could file a medical exception if switching is not suitable.
- Some employers with custom lists kept both.
The reaction
Lilly criticised the move and pointed members to its cash vials. The case became an example of how coverage, not only science, decides which drug people take.
Source CVS Health and Novo Nordisk announcements, 1 May 2025
Spotted an error? Tell us through the contact form; we follow the corrections policy.
